MatriSys Bioscience, Inc.

MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion WW dermatology and skin care market. We are developing therapies for the top 5 dermatology & skin care conditions - Atopic Dermatitis, Rosacea, Psoriasis, Acne, and Skin Infections, which have a huge impact on quality of life. More than 230 million patients suffer from these 5 skin diseases, which represent a $12.9 Billion Rx market and a $121 Billion skin care market. MatriSys Bio’s scientific approach is to rebalance the natural skin microbiome by application of microbial therapies -“Good Bugs” that selectively target skin pathogens -“Bad Bugs”. Our lead microbiome Phase I/II clinical program addresses the Atopic Dermatitis (“AD”) market with 15 M US patients (132 M worldwide), is NIH funded, and IP protected with an exclusive license from UCSD. Our “Good Bug”, S. hominis, is highly potent against the “Bad Bug”, Staph. aureus, which has long been associated with AD. S. hominis does not affect other “Good Bugs” leading to the natural rebalance of the skin microbiome.